lisdexamfetamine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 42 Diseases   12 Trials   12 Trials   1286 News 


«12345678910111213...1415»
  • ||||||||||  lisdexamfetamine / Generic mfg., dextroamphetamine immediate release / Generic mfg., phentermine / Generic mfg.
    Review, Journal:  The Therapeutic Potential of Amphetamine-like Psychostimulants. (Pubmed Central) -  Nov 25, 2023   
    In conclusion, amphetamine-type stimulants present a promising avenue for therapeutic interventions in various psychiatric conditions. Nevertheless, further research is necessary to comprehensively understand their mechanisms of action, dosage requirements, and long-term effects in different patient populations.
  • ||||||||||  lisdexamfetamine / Generic mfg., fluoxetine / Generic mfg.
    Review, Journal:  Eating Disorders. (Pubmed Central) -  Nov 22, 2023   
    Careful examination for and documentation of dental erosions, posterior oropharyngeal bruising, Russel's sign, and salivary and parotid gland inflammation are clues to the purging behavior. Treatment for AN should include cognitive behavioral therapy with concomitant efforts to treat any psychiatric comorbidities, whereas BN and BED have been successfully treated with fluoxetine and lisdexamfetamine, respectively.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Enrollment open:  Vyvanse in Children Aged 6 to 12 Years (clinicaltrials.gov) -  Nov 21, 2023   
    P1,  N=40, Recruiting, 
    The therapeutic effects of semaglutide in binge eating disorder warrant further investigation. Not yet recruiting --> Recruiting
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Enrollment change:  IMPRES: IMProving Executive Function Study (clinicaltrials.gov) -  Nov 18, 2023   
    P4,  N=69, Completed, 
    Not yet recruiting --> Recruiting N=133 --> 69
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Enrollment closed:  Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment (clinicaltrials.gov) -  Oct 26, 2023   
    P3,  N=80, Active, not recruiting, 
    In managing ADHD symptoms medication plays an essential role, including stimulants such as methylphenidate being a key component...Therefore, based on this data the consensus is that stimulant medications do generate manageable and mild negative outcomes within the Recruiting --> Active, not recruiting
  • ||||||||||  NN1213 / Novo Nordisk, Intuniv (guanfacine XR) / Shionogi, Takeda
    Trial completion:  ADAPT: ADHD Medication and Predictors of Treatment Outcome (clinicaltrials.gov) -  Oct 17, 2023   
    P=N/A,  N=632, Completed, 
    Initiation date: Jun 2023 --> Dec 2023 Active, not recruiting --> Completed
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  LAMAinDiab: Lisdexamphetamine vs Methylphenidate for Pediatric Patients With ADHD and Type 1 Diabetes (clinicaltrials.gov) -  Oct 10, 2023   
    P2,  N=150, Not yet recruiting, 
    Active, not recruiting --> Completed Trial completion date: Jul 2026 --> Dec 2027 | Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Jul 2026 --> Dec 2027
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Trial completion date, Trial primary completion date:  Vyvanse in Children Aged 6 to 12 Years (clinicaltrials.gov) -  Oct 3, 2023   
    P1,  N=40, Not yet recruiting, 
    Trial completion date: Jul 2026 --> Dec 2027 | Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Jul 2026 --> Dec 2027 Trial completion date: Jun 2029 --> Nov 2029 | Trial primary completion date: Jun 2028 --> Nov 2028
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism (clinicaltrials.gov) -  Sep 28, 2023   
    P4,  N=48, Active, not recruiting, 
    Trial completion date: Jun 2029 --> Nov 2029 | Trial primary completion date: Jun 2028 --> Nov 2028 Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Review, Journal:  Attention deficit hyperactivity: pharmacotherapy through life (Pubmed Central) -  Sep 20, 2023   
    Non-stimulants include guanfacine and atomoxetine. Treatment is essential because it improves the quality of life of the person at the family, educational, work, and social levels.
  • ||||||||||  bupropion / Generic mfg.
    Bupropion Poisoning: Extracorporeal Membrane Oxygenation as a Rescue Strategy (Zone 4, Science and Technology Hall, Level 2) -  Aug 12, 2023 - Abstract #AHA2023AHA_6118;    
    Case Presentation: A 29-year-old female with history of depression and borderline personality disorder presented to the emergency department unresponsive after ingesting large quantities of bupropion, alprazolam and lisdexamfetamine...She developed sustained ventricular tachycardia and hypotension, unresponsive to bicarbonate and amiodarone...Various approaches, including ECMO and lipid emulsion therapy, have been effectively employed in such cases. This case demonstrates that ECMO can serve as a hemodynamic bridge during the elimination of bupropion while augmenting its clearance via increased flow, underscoring the benefits of mechanical circulatory support in cases of intoxication affecting cardiac contractility and conduction.
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Journal:  Interaction of Diamine Oxidase with Psychostimulant Drugs for ADHD Management. (Pubmed Central) -  Jul 29, 2023   
    To sum up, methylphenidate and lisdexamfetamine treatments do not reduce DAO activity. These findings could be useful for physicians prescribing these two drugs to ADHD patients affected by DAO deficiency.
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Retrospective data, Review, Journal:  Psychopharmacology of eating disorders: Systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) -  Jul 17, 2023   
    In conclusion, our modeling results, despite their limitations and although requiring in vitro or in vivo validation, could supplement the design of preclinical and potentially clinical studies that investigate treatment for patients with ADHD with psychiatric comorbidities, especially from a molecular point of view. The efficacy of different drugs varies across different EDs, warranting additional primary studies recording broad psychopathological and cardiometabolic outcomes besides weight, especially against established psychotherapy interventions.
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Journal:  Salience and hedonic experience as predictors of central stimulant treatment response in ADHD - A resting state fMRI study. (Pubmed Central) -  Jun 12, 2023   
    In conclusion, an immediate-released, child-friendly lisdexamfetamine chewable tablets without bitterness was successfully developed by the QbD approach, using the SeDeM system, which may help in further development of chewable tablets. Incentive salience and hedonic experience evaluated after a single-dose CS medication segregate CS responders and non-responders, with corresponding neuroimaging biomarkers in the brain reward system.
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Journal:  Psychostimulants: An Overview (Pubmed Central) -  May 21, 2023   
    A psychosocial approach is considered the mainstay of treatment for attention-deficit/hyperactivity disorder (ADHD), and medication is used to treat moderate or severe ADHD symptoms. Two of the four drugs approved in Japan for ADHD therapy (osmotic-release oral system methylphenidate and lisdexamfetamine dimesylate) are psychostimulants, which are administered via the ADHD proper distribution management system.
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Journal, Real-world evidence, Real-world:  Association of pharmacological treatments and real-world outcomes in borderline personality disorder. (Pubmed Central) -  May 17, 2023   
    ADHD medications were associated with a reduced risk of psychiatric rehospitalization or hospitalization owing to any cause or death among individuals with BPD. No such associations were found for benzodiazepines, antidepressants, antipsychotics, or mood stabilizers.
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Objectifying the Day Response Variation of (Lis)Dexamphetamine in Adults With ADHD (Hall B Foyer, Exhibition Level Moscone South) -  May 17, 2023 - Abstract #APA2023APA_1439;    
    P=N/A
    In practice, the optimal dosage for stimulants is up-titrated until maximal efficacy and minimal side effects are achieved, which are based on the subjective effects experienced by patients. The current data showed that D-AMPH is more likely to induce craving and dysphoric effects in patients and, as such, will be more prone to pursue higher or multiple doses of D-AMPH.
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Covid-19 Related Psychosis in a Young Patient With a History of Viral Encephalopathy (Hall B Foyer, Exhibition Level Moscone South) -  May 17, 2023 - Abstract #APA2023APA_817;    
    The current data showed that D-AMPH is more likely to induce craving and dysphoric effects in patients and, as such, will be more prone to pursue higher or multiple doses of D-AMPH. In the hospital, patient
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    A Case of Gingko Induced Vyvanse Psychosis (Hall B Foyer, Exhibition Level Moscone South) -  May 17, 2023 - Abstract #APA2023APA_489;    
    Here we describe a case report of a 64-year-old patient on Gingko and recently started on Lisdexamphetamine for inattention symptoms, who presented with altered sensorium, new onset visual and auditory hallucinations. Here we suggest these drug interactions being responsible for the presenting amphetamine toxicity.
  • ||||||||||  Imcivree (setmelanotide) / Rhythm Pharma
    Treatment History and Comorbidities Reported by Patients With Hypothalamic Obesity Treated With Setmelanotide in a Phase 2 Trial (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_1867;    
    P2
    Thirteen patients (72.2%) reported prior lifestyle modifications (ie, calorie restriction [n=4], low-carbohydrate diet [n=6], dietary tracking/modification [n=4], food access restriction [n=1], personal training [n=1]) and/or pharmacotherapy use (ie, exenatide [n=3], semaglutide [n=1], liraglutide [n=2], metformin [n=2], methylphenidate [n=2], dextroamphetamine [n=1], lisdexamfetamine [n=2], naltrexone [n=3], oxytocin [n=3], phentermine [n=1]) without substantial benefit. Despite complex medical histories, hypothalamic damage, and various prior failed interventions, setmelanotide reduced BMI in patients with HO in a Phase 2 trial.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Trial completion:  IDEAL: The Day-time Response Variation of (Lis)Dexamphetamine (clinicaltrials.gov) -  May 10, 2023   
    P=N/A,  N=16, Completed, 
    The most promising CIM interventions are traditional yoga, virtual reality, eye movement desensitization and reprocessing, Music Therapy, and biofeedback/neurofeedback. Recruiting --> Completed
  • ||||||||||  Qelbree (viloxazine) / Supernus Pharma
    Journal:  Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research. (Pubmed Central) -  Apr 26, 2023   
    At present, the limited existing literature suggests that psychostimulants such as methylphenidate and lisdexamfetamine, as well as atomoxetine, may improve CDS symptoms, although replication and research on related medications is needed...Although untested, research on the neurobiological, neuropsychological, and behavioral correlates of CDS point to a possible benefit of other ADHD medications (e.g., guanfacine), medications that treat narcolepsy (e.g., modafinil), and medications traditionally used to treat depression and anxiety (e.g., viloxazine, bupropion, fluvoxamine), some of which have also recently been used in ADHD management. The article concludes with recommendations for future research on pharmacologic treatment and CDS.